Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Biotechnology

Healthcare
$2.29 +0.67%

+$0.02 today

Market cap
$165.63M
Beta
0.35
P/E (TTM)
-1.3
EPS (TTM)
-$1.79
52W Low $1.10High $3.60

Volume 0.81M

Average 0.40M

ABOS Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Acumen Pharmaceuticals, Inc.NASDAQ: ABOS

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

No Operating Margin data reported for this period type.

Operating Margin vs competitors

How ABOS compares with its peers on the latest reported figures

ABOS Competitors Peer median
Operating Margin for ABOS and competitors
Company Period LTM level YoY 3-year change
SPROSpero Therapeutics, Inc.LTM Mar 202624.7% +190.9 pp+86.8 pp
AGENAgenus Inc.LTM Mar 20266.6% +108.0 pp+165.0 pp
IRDOpus Genetics, Inc.LTM Mar 2026-359.1% +111.9 pp-317.6 pp
SEERSeer, Inc.LTM Mar 2026-496.4% +134.5 pp+180.9 pp
ALECAlector, Inc.LTM Mar 2026-741.3% -576.1 pp-589.7 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2207.5% -704.0 pp-1902.2 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-7641.0% ——
INOInovio Pharmaceuticals, Inc.FY2025-132871.3% -81254.4 pp-130264.0 pp
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding ABOS) -618.9%+108.0 pp-317.6 pp

Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue12.31M0000
Gross Profit(12.31M)0000
Gross Margin—————
Research & Development12.31M32.36M42.32M93.8M104.89M
Selling, General & Admin7.28M12.88M18.82M20.22M18.95M
Operating Expenses7.28M45.24M61.14M114.02M123.83M
Depreciation & Amortization4K169K184K178K184K
EBITDA(100.6M)(42.69M)(51.61M)(98.08M)(116.93M)
EBITDA Margin—————
Operating Income(19.58M)(45.24M)(61.14M)(114.02M)(123.83M)
Operating Margin—————
Interest Income84K2.39M10.79M14.32M7.45M
Interest Expense00581K4.07M4.22M
Other Income / Expenses(81.02M)2.38M8.77M11.69M2.5M
Income Before Tax(100.61M)(42.86M)(52.37M)(102.33M)(121.34M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(100.61M)(42.86M)(52.37M)(102.33M)(121.34M)
Net Margin—————
EPS (Basic)(2.63)(1.06)(1.08)(1.71)(2.00)
EPS (Diluted)(2.63)(1.06)(1.08)(1.71)(2.00)
Weighted Avg Shares38.27M40.6M48.49M60.01M60.56M
Weighted Avg Shares (Diluted)38.27M40.6M48.61M60.01M60.56M

Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Intrinsic Alpha fair value

Locked

Current Price

$2.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.